<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955939</url>
  </required_header>
  <id_info>
    <org_study_id>17249</org_study_id>
    <secondary_id>J1O-MC-JZHC</secondary_id>
    <secondary_id>2018-004183-61</secondary_id>
    <nct_id>NCT03955939</nct_id>
  </id_info>
  <brief_title>A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body</brief_title>
  <official_title>A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to determine the recommended phase 2 dose of the study drug
      LY3295668 erbumine in participants with breast cancer that has spread to other parts of the
      body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Actual">May 14, 2020</completion_date>
  <primary_completion_date type="Actual">May 14, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Reductions</measure>
    <time_frame>Baseline through Cycle 1 (28 Day Cycle)</time_frame>
    <description>Number of Participants with Dose Reductions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 1 (28 Day Cycle)</time_frame>
    <description>Part II: Number of Participants with DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 23 Months)</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Estimated up to 23 Months)</time_frame>
    <description>DoR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR): Percentage of Participants Who Achieve CR, PR or SD With a Duration of At Least 6 Months</measure>
    <time_frame>Baseline through Disease Progression or Death Due to Any Cause (Estimated up to 23 Months)</time_frame>
    <description>CBR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 23 Months)</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3295668</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: AUC of LY3295668</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of LY3295668 in Combination with Endocrine Therapy</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: AUC of LY3295668 in Combination with Endocrine Therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Endocrine Therapy in Combination with LY3295668</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: AUC of Endocrine Therapy in Combination with LY3295668</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Midazolam</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: AUC of Midazolam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Midazolam in Combination with LY3295668</measure>
    <time_frame>Predose Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: AUC of Midazolam in Combination with LY3295668</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>LY3295668 Erbumine Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3295668 erbumine administered orally (Part I).
Approximately the first 10 participants enrolled in this arm will be administered midazolam.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3295668 Erbumine Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3295668 erbumine administered orally (Part I).
Approximately the first 10 participants enrolled in this arm will be administered midazolam.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3295668 Erbumine + Endocrine Therapy Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part II).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3295668 Erbumine + Endocrine Therapy Continuation Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3295668 Erbumine + Endocrine Therapy Switch Part D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3295668 erbumine administered orally and endocrine therapy administered according to package label (Part I).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3295668 Erbumine</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3295668 Erbumine + Endocrine Therapy Cohort 1</arm_group_label>
    <arm_group_label>LY3295668 Erbumine + Endocrine Therapy Continuation Part C</arm_group_label>
    <arm_group_label>LY3295668 Erbumine + Endocrine Therapy Switch Part D</arm_group_label>
    <arm_group_label>LY3295668 Erbumine Part A</arm_group_label>
    <arm_group_label>LY3295668 Erbumine Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine therapy</intervention_name>
    <description>Administered according to label instructions.</description>
    <arm_group_label>LY3295668 Erbumine + Endocrine Therapy Cohort 1</arm_group_label>
    <arm_group_label>LY3295668 Erbumine + Endocrine Therapy Continuation Part C</arm_group_label>
    <arm_group_label>LY3295668 Erbumine + Endocrine Therapy Switch Part D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3295668 Erbumine Part A</arm_group_label>
    <arm_group_label>LY3295668 Erbumine Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have hormone receptor positive and HER2 negative metastatic breast
             cancer

          -  Participant must have progressed on at least 1 line of endocrine therapy and 1 cyclin
             dependent kinase (CDK)4/6 inhibitor

          -  Participant must be able and willing to undergo mandatory tumor biopsy

          -  Participant must have normal organ function

          -  Participant must be able to swallow capsules

        Exclusion Criteria:

          -  Participant must not have had prior chemotherapy for mBC. Chemotherapy in the
             adjuvant/neoadjuvant setting is permitted

          -  Participant must not be currently enrolled in a clinical study

          -  Participant must not have another serious medical condition

          -  Participant must not have previously received an aurora kinase inhibitor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-0269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/metastatic-breast-cancer/JZHC</url>
    <description>A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aurora kinase A</keyword>
  <keyword>kinase</keyword>
  <keyword>aurora A</keyword>
  <keyword>aurora kinase inhibitor</keyword>
  <keyword>aurora kinase A inhibitor</keyword>
  <keyword>kinase inhibitor</keyword>
  <keyword>AURKA</keyword>
  <keyword>AurA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

